We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.44%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$553M
AUM Growth
+$22M
Cap. Flow
-$5.91M
Cap. Flow %
-1.07%
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.16M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$4.22M
3
AKRX
Akorn Inc
AKRX
+$3.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.21M
5
ENDP
Endo International plc
ENDP
+$2.74M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$6.62M
2
CAH icon
Cardinal Health
CAH
+$6.02M
3
MDVN
MEDIVATION, INC.
MDVN
+$4.7M
4
STJ
St Jude Medical
STJ
+$4.68M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 92.11%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
76
DELISTED
bluebird bio
BLUE
$1.97M 0.36%
2,239
– –
ACHN
77
DELISTED
Achillion Pharmaceuticals
ACHN
$1.94M 0.35%
240,000
-180,000
-43% -$1.53M
HUM icon
78
Humana
HUM
$48B
$1.91M 0.35%
10,800
-19,200
-64% -$3.33M
AET
79
DELISTED
Aetna Inc
AET
$1.89M 0.34%
16,400
-9,500
-37% -$1.11M
WMGI
80
DELISTED
Wright Medical Group Inc
WMGI
$1.73M 0.31%
70,309
– –
PFE icon
81
Pfizer
PFE
$143B
$1.69M 0.31%
52,700
– –
ALNY icon
82
Alnylam Pharmaceuticals
ALNY
$35.7B
$1.63M 0.29%
24,000
– –
CLVS
83
DELISTED
Clovis Oncology, Inc.
CLVS
$1.55M 0.28%
+43,000
New +$923K
HCSG icon
84
Healthcare Services Group
HCSG
$1.74B
$1.51M 0.27%
38,100
– –
INO icon
85
Inovio Pharmaceuticals
INO
$92.1M
$1.45M 0.26%
12,917
– –
ACAD icon
86
Acadia Pharmaceuticals
ACAD
$4.38B
$1.43M 0.26%
45,000
– –
INSY
87
DELISTED
Insys Therapeutics, Inc.
INSY
$1.36M 0.25%
+115,000
New +$1.75M
ALR
88
DELISTED
Alere Inc
ALR
$1.3M 0.23%
30,000
– –
BMY icon
89
Bristol-Myers Squibb
BMY
$124B
$1.24M 0.22%
23,000
– –
LABU icon
90
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$1.23M 0.22%
1,259
-1,500
-54% -$1.24M
JUNO
91
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.11M 0.2%
37,000
– –
LH icon
92
Labcorp
LH
$23.2B
$1.1M 0.2%
9,312
– –
TFX icon
93
Teleflex
TFX
$5.96B
$1.09M 0.2%
6,500
-3,510
-35% -$629K
ALDR
94
DELISTED
Alder Biopharmaceuticals
ALDR
$1.08M 0.2%
33,000
– –
MOH icon
95
Molina Healthcare
MOH
$11.7B
$962K 0.17%
+16,500
New +$909K
ABBV icon
96
AbbVie
ABBV
$450B
$946K 0.17%
15,000
– –
EVHC
97
DELISTED
Envision Healthcare Holdings Inc
EVHC
$869K 0.16%
13,026
– –
CVS icon
98
CVS Health
CVS
$137B
$863K 0.16%
9,700
-70,100
-88% -$6.62M
QTNT
99
DELISTED
Quotient Limited Ordinary Shares
QTNT
$860K 0.16%
2,750
+250
+10% +$70.3K
PTLA
100
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$818K 0.15%
+36,000
New +$845K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2016 Portfolio in Review

As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials.

  • Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
  • Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
  • Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
  • Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
  • Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
  • Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
  • Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.